1-14 of 14
Joseph P. Eder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2969.
https://doi.org/10.1158/1078-0432.CCR-22-1792
Published: 01 July 2022
View articletitled, Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Journal Articles

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6366–6375.
https://doi.org/10.1158/1078-0432.CCR-20-4185
Published: 01 December 2021
View articletitled, A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors

Sara M. Tolaney, Khanh T. Do, Joseph P. Eder, Patricia M. LoRusso, Colin D. Weekes, Sarat Chandarlapaty, Ching-Wei Chang, Shang-Chiung Chen, Denise Nazzal, Eva Schuth, Flavia Brunstein, Montserrat Carrasco-Triguero, Walter C. Darbonne, Jennifer M. Giltnane, William M. Flanagan, S. Renee Commerford, Alexander Ungewickell, Geoffrey I. Shapiro, Shanu Modi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (21): 5588–5597.
https://doi.org/10.1158/1078-0432.CCR-20-1067
Published: 02 November 2020
View articletitled, A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Open the PDF for A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1

Neeta Somaiah, Matthew S. Block, Joseph W. Kim, Geoffrey I. Shapiro, Khanh T. Do, Patrick Hwu, Joseph P. Eder, Robin L. Jones, Hailing Lu, Jan H. ter Meulen, Chet Bohac, Michael Chen, Frank J. Hsu, Sacha Gnjatic, Seth M. Pollack
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (19): 5808–5817.
https://doi.org/10.1158/1078-0432.CCR-19-1025
Published: 01 October 2019
View articletitled, First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Open the PDF for First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 in another window
Includes: Supplementary data
Journal Articles

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae-Won Han, Karen Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P. Eder, Sunil Sharma, Yung-Jue Bang, Jeffrey R. Infante, Li Yan, Johann S. de Bono, Hendrik-Tobias Arkenau
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (19): 5981–5992.
https://doi.org/10.1158/1078-0432.CCR-17-0725
Published: 01 October 2017
View articletitled, A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs

Juliane M. Jürgensmeier, Joseph P. Eder, Roy S. Herbst
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4425–4435.
https://doi.org/10.1158/1078-0432.CCR-13-0753
Published: 01 September 2014
View articletitled, New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Open the PDF for New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs in another window
Journal Articles

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Munster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael J. Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2552–2558.
https://doi.org/10.1158/1078-0432.CCR-08-1978
Published: 01 April 2009
View articletitled, A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Open the PDF for A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors in another window
Journal Articles

Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors

Anna Berkenblit, Joseph P. Eder, Jr., David P. Ryan, Michael V. Seiden, Noriaki Tatsuta, Matthew L. Sherman, Thomas A. Dahl, Bruce J. Dezube, Jeffrey G. Supko
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 584–590.
https://doi.org/10.1158/1078-0432.CCR-06-0964
Published: 25 January 2007
View articletitled, Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors
Open the PDF for Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors in another window
Journal Articles

A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

Linda L. Garland, Manuel Hidalgo, David S. Mendelson, David P. Ryan, Banu K. Arun, Jennifer L. Lovalvo, Irene A. Eiseman, Stephen C. Olson, Peter F. Lenehan, Joseph P. Eder
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4274–4282.
https://doi.org/10.1158/1078-0432.CCR-05-2507
Published: 20 July 2006
View articletitled, A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Casey Cunningham, Leonard J. Appleman, Miora Kirvan-Visovatti, David P. Ryan, Eileen Regan, Svetislava Vukelja, Peter L. Bonate, Francis Ruvuna, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7825–7833.
https://doi.org/10.1158/1078-0432.CCR-05-0058
Published: 08 November 2005
View articletitled, Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

Jeffrey W. Clark, Joseph P. Eder, David Ryan, Chetan Lathia, Heinz-Josef Lenz
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5472–5480.
https://doi.org/10.1158/1078-0432.CCR-04-2658
Published: 01 August 2005
View articletitled, Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors
Open the PDF for Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors in another window
Journal Articles

Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors

David P. Ryan, Joseph P. Eder, Jr., Thomas Puchlaski, Michael V. Seiden, Thomas J. Lynch, Charles S. Fuchs, Philip C. Amrein, Darrell Sonnichsen, Jeffrey G. Supko, Jeffrey W. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2222–2230.
https://doi.org/10.1158/1078-0432.CCR-0980-3
Published: 08 April 2004
View articletitled, Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
Open the PDF for Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors

Jeffrey G. Supko, Joseph P. Eder, Jr., David P. Ryan, Michael V. Seiden, Thomas J. Lynch, Phillip C. Amrein, Donald W. Kufe, Jeffrey W. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5178–5186.
Published: 12 November 2003
View articletitled, Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors
Open the PDF for Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors in another window
Journal Articles

A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors

Michael V. Seiden, Shu-Wing Ng, Jeffrey G. Supko, David P. Ryan, Jeffrey W. Clark, Thomas Lynch, Kuan-Chun Huang, David Kwiatkowski, Arthur Skarin, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 691–697.
Published: 01 March 2002
View articletitled, A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors
Open the PDF for A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors in another window